Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,365,514

« Back to Dashboard

Which drugs does patent 9,365,514 protect, and when does it expire?

Patent 9,365,514 protects ALECENSA and is included in one NDA.

This patent has twenty-one patent family members in seventeen countries.

Summary for Patent: 9,365,514

Title:Composition comprising tetracyclic compound
Abstract: A composition which comprises substance represented by Formula (I), ##STR00001## [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.
Inventor(s): Furumoto; Kentaro (Gotemba, JP), Shiraki; Koji (Gotemba, JP), Hirayama; Tomoaki (Tokyo, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:13/816,804
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann-la RocheALECENSAalectinib hydrochlorideCAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,365,514

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2010-185385Aug 20, 2010
PCT Information
PCT FiledAugust 19, 2011PCT Application Number:PCT/JP2011/068735
PCT Publication Date:February 23, 2012PCT Publication Number: WO2012/023597

International Patent Family for Patent: 9,365,514

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina083246► Subscribe
Australia2011291708► Subscribe
Brazil112013003879► Subscribe
Canada2808210► Subscribe
China103052386► Subscribe
European Patent Office2606886► Subscribe
Hong Kong1179878► Subscribe
Japan4918630► Subscribe
JapanWO2012023597► Subscribe
South Korea101362589► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: